CAS 238750-77-1 Tosedostat - Analytical Products / Alfa Chemistry

CAT	AP238750771
CAS	238750-77-1
Structure
MDL Number	MFCD13185162
Molecular Weight	406.47

Description	≥98% (HPLC)
Solubility	DMSO: 2 mg/mL, clear
Assay	≥98% (HPLC)
Color	white to beige
Form	powder
Size	5MG, 25MG
Storage Conditions	−20°C

1

A Phase Ib Dose-Escalation Study to Evaluate Safety and Tolerability of the Addition of the Aminopeptidase Inhibitor Tosedostat (CHR-2797) to Paclitaxel in Patients With Advanced Solid Tumours

C M L van Herpen, F A L M Eskens, M de Jonge, I Desar, L Hooftman, E A Bone, J N H Timmer-Bonte, J Verweij

Br J Cancer. 2010 Oct 26;103(9):1362-8.

PMID: 20877350

1

Emerging Therapies for Acute Myeloid Leukemia

Caner Saygin, Hetty E Carraway

J Hematol Oncol. 2017 Apr 18;10(1):93.

PMID: 28420416

1

Phase II Study of Tosedostat With Cytarabine or Decitabine in Newly Diagnosed Older Patients With Acute Myeloid Leukaemia or High-Risk MDS

Raya Mawad, Pamela S Becker, Paul Hendrie, Bart Scott, Brent L Wood, Carol Dean, Vicky Sandhu, Hans Joachim Deeg, Roland Walter, Lixia Wang, Han Myint, Jack W Singer, Elihu Estey, John M Pagel

Br J Haematol. 2016 Jan;172(2):238-45.

PMID: 26568032

1

Positioning of Aminopeptidase Inhibitors in Next Generation Cancer Therapy

Sarina M Hitzerd, Sue Ellen Verbrugge, Gert Ossenkoppele, Gerrit Jansen, Godefridus J Peters

Amino Acids. 2014 Apr;46(4):793-808.

PMID: 24385243

1

Two Dosing Regimens of Tosedostat in Elderly Patients With Relapsed or Refractory Acute Myeloid Leukaemia (OPAL): A Randomised Open-Label Phase 2 Study

Jorge Cortes, Eric Feldman, Karen Yee, David Rizzieri, Anjali S Advani, Anthony Charman, Richard Spruyt, Martin Toal, Hagop Kantarjian

Lancet Oncol. 2013 Apr;14(4):354-62.

PMID: 23453583

* Products or Services Interested: Tosedostat (238750-77-1)
* Your question
* Name
* Email
Verification Code